<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867020</url>
  </required_header>
  <id_info>
    <org_study_id>LACOG 0415</org_study_id>
    <nct_id>NCT02867020</nct_id>
  </id_info>
  <brief_title>Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels</brief_title>
  <official_title>Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Latin American Cooperative Oncology Group</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone,
      abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in
      hormone naïve locally advanced or metastatic prostate cancer which ADT was indicated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the current guidelines, ADT alone or combined with is antiandrogens are considered
      the appropriate active therapy for the patient population planned for this study. Recent data
      showed that chemotherapy also benefit patients in this setting. Even though, there is a clear
      unmet medical need for alternative treatment option in metastatic hormone sensitive prostate
      cancer (mHSPC). Treatments that can delay disease progression, and are associated with less
      comorbidities would be of significant clinical benefit in this patient population. The study
      is designed to assess the efficacy and safety of abiraterone plus APALUTAMIDE (a
      second-generation antiandrogen) or APALUTAMIDE alone without castration side effects and the
      other arm a combination of ADT and abiraterone; this last arm is to reflect an Abiraterone
      ongoing pivotal trial (LATITUDE), that assess the efficacy of adding abiraterone to
      castration in this setting of patients. Abiraterone had already showed clinical benefit in
      CRPC patients without prior chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that achieves an undetectable PSA level, defined as ≤ 0.2 ng/mL</measure>
    <time_frame>Week 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA progression rate</measure>
    <time_frame>Week 25</time_frame>
    <description>Determination of PSA progression rate among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PSA progression rate</measure>
    <time_frame>Week 25</time_frame>
    <description>Comparison of PSA progression rate among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA response of 50 and 80%</measure>
    <time_frame>Week 25</time_frame>
    <description>Determination of PSA response of 50 and 80% among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of PSA response of 50 and 80%</measure>
    <time_frame>Week 25</time_frame>
    <description>Comparison of PSA response of 50 and 80% among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum PSA declines</measure>
    <time_frame>Baseline up to week 25 to 52</time_frame>
    <description>Determination of maximum PSA declines among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall PSA change</measure>
    <time_frame>Baseline up to week 25 to 52</time_frame>
    <description>Determination of overall PSA change among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal levels during treatment</measure>
    <time_frame>Baseline up to week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of hormonal levels during treatment</measure>
    <time_frame>Baseline up to week 25</time_frame>
    <description>Comparison of hormonal levels during treatment among the three experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of bone mineral density according to RECIST 1.1</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of bone mineral density according to RECIST 1.1 between three experimental groups</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Baseline to 2 years of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with pain progression assessed by BPI-SF of three experimental arms</measure>
    <time_frame>Baseline up to week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants in opioid use during treatment among three experimental arms</measure>
    <time_frame>Baseline up to week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pain progression assessed by opioid use</measure>
    <time_frame>Baseline up to week 25</time_frame>
    <description>Comparison of pain progression assessed by opioid use between the experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of pain progression assessed by BPI-SF questionnaire</measure>
    <time_frame>Baseline up to week 25</time_frame>
    <description>Comparison of pain progression assessed by BPI-SF between the experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by FACT-P questionnaire</measure>
    <time_frame>Baseline up to week 25</time_frame>
    <description>Quality of life assessed by FACT-P questionnaire of the experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life assessed by FACT-P questionnaire</measure>
    <time_frame>Baseline up to week 25</time_frame>
    <description>Comparison of quality of life assessed by FACT-P questionnaire between the experimental arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>Week 25</time_frame>
    <description>Radiographic progression-free survival (rPFS) among the experimental arms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone acetate + Prednisone + ADT (Goserelin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)
Prednisone administered at a 5 mg twice daily oral dose
Goserelin administered as subcutaneous injections of 10.8mg every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APALUTAMIDE monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone acetate + Prednisone + APALUTAMIDE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)
Prednisone administered at a 5 mg twice daily oral dose
APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.</description>
    <arm_group_label>Abiraterone acetate + Prednisone + ADT (Goserelin)</arm_group_label>
    <arm_group_label>APALUTAMIDE monotherapy</arm_group_label>
    <arm_group_label>Abiraterone acetate + Prednisone + APALUTAMIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days</description>
    <arm_group_label>Abiraterone acetate + Prednisone + ADT (Goserelin)</arm_group_label>
    <arm_group_label>Abiraterone acetate + Prednisone + APALUTAMIDE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT</intervention_name>
    <description>Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).</description>
    <arm_group_label>Abiraterone acetate + Prednisone + ADT (Goserelin)</arm_group_label>
    <other_name>Goserelin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Subjects will receive prednisone 10mg/day.</description>
    <arm_group_label>Abiraterone acetate + Prednisone + APALUTAMIDE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed prostate adenocarcinoma;

          2. Hormone naïve patients with indication to ADT in the following settings:

               -  Advanced loco-regional disease not amenable to curative local therapy (surgery or
                  radiotherapy): T category T3/4 or node positive

               -  Biochemical relapse after primary treatment (surgery or radiotherapy): patients
                  in whom primary therapy is not appropriate or feasible with Previously treated
                  with radical surgery and/or radiotherapy, now relapsing with at least one of the
                  criteria: PSA &gt;= 4 ng/ml and rising with doubling time less than 10 months. or
                  PSA &gt;= 20 ng/ml or N+ or M+

               -  Newly diagnosed metastatic disease: Tany Nany M+

          3. Patient is asymptomatic or moderately symptomatic regarding bone symptoms, i.e., no
             need for palliative radiation or radionuclide therapy;

          4. Non-castration level of testosterone &gt; 230ng/dL (&gt; 8 nmol/L);

          5. Baseline level of prostatespecific antigen (PSA) &gt; 2ng/dL;

          6. ECOG performance status of 0 to 2;

          7. Adequate hematologic, hepatic and renal function:

               1. hemoglobin &gt; 10 g/dL, neutrophils &gt; 1.5×109 / L, platelets&gt; 100×109 / L;

               2. total bilirubin &lt; 1.5x upper limit of normal (ULN); alanine (ALT) and aspartate
                  (AST) aminotransferase &lt; 2.5 x ULN;

               3. serum creatinine &lt; 1.5x ULN; potassium &gt; 3.5 mM;

          8. No previous cancer (except treated basal-cell skin cancer);

          9. Written informed consent obtained prior to any study procedure;

         10. Men age 18 years and older;

         11. Agrees to use a condom and another effective method of birth control if he is having
             sex with a woman of childbearing potential or agrees to use a condom if he is having
             sex with a woman who is pregnant.

        Exclusion Criteria:

          1. Prostate adenocarcinoma with neuroendocrine differentiation or small cell histology;

          2. Biochemical recurrence without evidence of clinical or radiological disease;

          3. Use of hormonal therapy or chemotherapy prior to randomization. Exception is courses
             of hormone therapy for localised disease must have been completed at least 12 months
             previously. It can have been given as adjuvant or neoadjuvant therapy.

          4. Prior radiation therapy for a primary tumour within the 3 months before enrollment or
             for the treatment of metastases;

          5. Known or suspected brain or skull metastases or leptomeningeal metastatic disease;

          6. Any concurrent severe and/or uncontrolled medical conditions which could compromise
             participation in the study;

          7. Administration of an investigational therapeutic or invasive surgical procedure (not
             including surgical castration) within 28 days of Cycle 1 Day 1 or currently enrolled
             in an investigational study;

          8. Active or symptomatic viral hepatitis or chronic liver disease; ascites or bleeding
             disorders secondary to hepatic dysfunction;

          9. Current or prior treatment with anti-epileptic medications for the treatment of
             seizures;

         10. Impaired cardiac function, including any of the following:

               1. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥95
                  mmHg);

               2. Clinically significant heart disease as evidenced by myocardial infarction, or
                  arterial thrombotic events or history of cardiac failure in the past 6 months,
                  severe or unstable angina, or New York Heart Association (NYHA) Class II-IV heart
                  disease;

               3. Existing atrial fibrillation with or without pharmacotherapy. Other cardiac
                  arrhythmia requiring pharmacotherapy;

               4. History of seizure or condition that may predispose to seizure (including, but
                  not limited to prior stroke, transient ischemic attack or loss of consciousness
                  ≤1 year prior to randomization; brain arteriovenous malformation; or intracranial
                  masses such as schwannomas and meningiomas that are causing edema or mass
                  effect);

         11. Specific underlying conditions for oral agents. For example: impairment of
             gastrointestinal (GI) function or GI disease that may significantly alter the
             absorption of abiraterone or APALUTAMIDE (e.g., ulcerative diseases, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

         12. General excluded medications (e.g., relevant to cytochrome P450 interactions)

               1. Use of prescription drugs within 14 days prior to dosing or over-the-counter
                  (OTC) medication within 7 days prior to dosing;

               2. Consumption of grapefruit product or St John's wort within 7 days prior to
                  dosing;

               3. G-CSF, GM-CSF, erythropoietin, etc;

               4. Coumadin;

               5. Drugs which may cause QT prolongation;

               6. Known sensitivity to drugs or metabolites from similar classes;

               7. Known or suspected contraindications or hypersensitivity to APALUTAMIDE,
                  bicalutamide or GnRH agonists or any of the components of the formulations;

         13. Any condition or situation which, in the opinion of the investigator, would put the
             subject at risk, may confound study results, or interfere with the subject's
             participation in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Maluf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beneficiência Portuguesa de São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Werutsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Latin American Cooperative Oncology Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Voelcker</last_name>
    <phone>55 51 3384 5334</phone>
    <email>laura.voelcker@lacog.org.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raíra Maschmann</last_name>
    <phone>55 51 3384 5334</phone>
    <email>raira.maschmann@lacog.org.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica AMO</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Setenta</last_name>
    </contact>
    <investigator>
      <last_name>Vanessa Dybal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CRIO</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Gomes</last_name>
    </contact>
    <investigator>
      <last_name>Eduardo Cronemberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CPO - Pucrs</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Webber</last_name>
    </contact>
    <investigator>
      <last_name>André Fay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Rede D'Or S.A.</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22281 100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leandro Camara</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Herchenhorn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Câncer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Camila Alfano</last_name>
    </contact>
    <investigator>
      <last_name>Ricardo Zylberberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica em Hematologia e Oncologia - CEPHO</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andressa Tamashiro</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Cubero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grupo COI</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Débora Victorino</last_name>
    </contact>
    <investigator>
      <last_name>Fábio Peixoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beneficiencia Portuguesa de São Paulo/Hospital São José</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Molina</last_name>
    </contact>
    <contact_backup>
      <last_name>Daniel Lang</last_name>
    </contact_backup>
    <investigator>
      <last_name>Fernando Maluf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Possato</last_name>
    </contact>
    <investigator>
      <last_name>Oren Smaletz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bárbara Penna</last_name>
    </contact>
    <investigator>
      <last_name>David Muniz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, Barlow WE, Blanke C, Thompson IM, Hussain M. Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol. 2016 Apr;2(4):453-61. doi: 10.1001/jamaoncol.2015.4655.</citation>
    <PMID>26720308</PMID>
  </reference>
  <reference>
    <citation>Rozet F, Roumeguère T, Spahn M, Beyersdorff D, Hammerer P. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management. World J Urol. 2016 Nov;34(11):1505-1513. Epub 2016 Mar 17. Review.</citation>
    <PMID>26988552</PMID>
  </reference>
  <reference>
    <citation>Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.</citation>
    <PMID>26196735</PMID>
  </reference>
  <reference>
    <citation>Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov;68(5):850-8. doi: 10.1016/j.eururo.2015.06.039. Epub 2015 Jul 4. Review.</citation>
    <PMID>26153564</PMID>
  </reference>
  <reference>
    <citation>Barrie SE, Potter GA, Goddard PM, Haynes BP, Dowsett M, Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73.</citation>
    <PMID>7918112</PMID>
  </reference>
  <reference>
    <citation>Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009 Aug 10;27(23):3742-8. doi: 10.1200/JCO.2008.20.0642. Epub 2009 May 26.</citation>
    <PMID>19470933</PMID>
  </reference>
  <reference>
    <citation>Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. Erratum in: J Clin Oncol. 2012 May 20;30(15):1896.</citation>
    <PMID>18645193</PMID>
  </reference>
  <reference>
    <citation>Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.</citation>
    <PMID>20159814</PMID>
  </reference>
  <reference>
    <citation>O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004 Jun 14;90(12):2317-25.</citation>
    <PMID>15150570</PMID>
  </reference>
  <reference>
    <citation>Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010 Mar 20;28(9):1489-95. doi: 10.1200/JCO.2009.24.6819. Epub 2010 Feb 16.</citation>
    <PMID>20159823</PMID>
  </reference>
  <reference>
    <citation>Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15;17(14):4854-61. doi: 10.1158/1078-0432.CCR-11-0815. Epub 2011 Jun 1.</citation>
    <PMID>21632851</PMID>
  </reference>
  <reference>
    <citation>Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20;28(9):1481-8. doi: 10.1200/JCO.2009.24.1281. Epub 2010 Feb 16.</citation>
    <PMID>20159824</PMID>
  </reference>
  <reference>
    <citation>de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618.</citation>
    <PMID>21612468</PMID>
  </reference>
  <reference>
    <citation>Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. doi: 10.1016/S1470-2045(12)70379-0. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365.</citation>
    <PMID>22995653</PMID>
  </reference>
  <reference>
    <citation>Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. doi: 10.1056/NEJMoa1209096. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.</citation>
    <PMID>23228172</PMID>
  </reference>
  <reference>
    <citation>Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.</citation>
    <PMID>24002508</PMID>
  </reference>
  <reference>
    <citation>Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.</citation>
    <PMID>22266222</PMID>
  </reference>
  <reference>
    <citation>Rathkopf DE, Antonarakis ES, Shore ND, et al: ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 31:abstr 48, 2013</citation>
  </reference>
  <reference>
    <citation>Efstathiou E, Titus MA, Wen S, et al: Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 32:abstr 5000, 2014</citation>
  </reference>
  <reference>
    <citation>Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014 May;15(6):592-600. doi: 10.1016/S1470-2045(14)70129-9. Epub 2014 Apr 14.</citation>
    <PMID>24739897</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>apalutamide</keyword>
  <keyword>abiraterone</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

